Insider Trading February 13, 2026

Nucor Executive Vice President Disposes $1.46 Million in Shares Amid Q4 Miss

Senior executive sells 7,452 shares as company posts fourth-quarter 2025 results below expectations

By Ajmal Hussain NUE
Nucor Executive Vice President Disposes $1.46 Million in Shares Amid Q4 Miss
NUE

Nucor Corp Executive Vice President Kenneth Rex Query sold 7,452 shares of company stock on February 11, 2026, realizing approximately $1.46 million. The transaction occurred at a weighted average price of $196.0194 per share and left Query with 76,628 shares of Nucor stock. Separately, Nucor reported fourth-quarter 2025 results that missed analyst projections for both earnings per share and revenue.

Key Points

  • Executive Vice President Kenneth Rex Query sold 7,452 Nucor shares on February 11, 2026, at a weighted average price of $196.0194, totaling about $1.46 million.
  • Following the sale, Query directly owns 76,628 shares of Nucor stock.
  • Nucor's fourth-quarter 2025 results missed expectations, with EPS of $1.73 versus $1.86 forecast and revenue of $7.69 billion versus $7.87 billion expected - developments relevant to the steel and industrial materials sectors.

Summary: Nucor Corp reported an insider sale by Executive Vice President Kenneth Rex Query on February 11, 2026, and disclosed quarterly results for Q4 2025 that fell short of analyst expectations. The sale and the quarterly miss are noted developments for investors and market watchers.


Insider transaction details

According to the filing, Query sold a total of 7,452 shares of Nucor common stock on February 11, 2026. The shares changed hands at a weighted average price of $196.0194, producing a cumulative transaction value of approximately $1.46 million. The execution prices for those shares ranged between $195.9501 and $196.3350.

After completing the sale, Query directly holds 76,628 shares of Nucor stock.


Quarterly financial results

Nucor released fourth-quarter 2025 financial results that did not meet market expectations. Reported earnings per share for the quarter were $1.73, below the projected $1.86. Quarterly revenue came in at $7.69 billion versus an anticipated $7.87 billion. The company therefore missed consensus estimates on both EPS and revenue for the period.


Market context and potential implications

The combination of an insider sale and a quarter that missed projections represents new information for shareholders and analysts following Nucor. As noted in the filings and results disclosures, these are recent developments that may influence investor sentiment and the future assessments conducted by financial analysts. At the time of the report, there were no announced analyst upgrades or downgrades following the release of the quarterly figures.


What we know and what we do not know

The public disclosures provide the exact quantity of shares sold, the price range and weighted average, the remaining direct holdings of the executive, and the headline quarterly figures with their comparisons to expectations. They do not include additional commentary from company management about the results or any explanatory detail tied directly to the insider sale.

This article remains strictly confined to the information reported in company filings and the published quarterly numbers.

Risks

  • Earnings and revenue came in below expectations for Q4 2025, which could affect investor confidence in Nucor's near-term financial performance - impacting the steel and industrial materials sectors.
  • The insider sale and the quarterly miss are recent developments that may influence investor sentiment and prompt reevaluation by analysts, introducing short-term uncertainty for Nucor's stock.
  • No immediate analyst upgrades or downgrades were reported following the results, leaving professional assessments and market reaction uncertain in the near term.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026